Related references
Note: Only part of the references are listed.A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan et al.
BLOOD (2013)
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
A. K. Burnett et al.
LEUKEMIA (2013)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia
Sang Hyuk Park et al.
LEUKEMIA RESEARCH (2011)
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
Jessica A. Pollard et al.
BLOOD (2010)
KIT mutations confer a distinct gene expression signature in core binding factor leukaemia
Sonja C. Lueck et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Treatment of Core-Binding-Factor in Acute Myelogenous Leukemia With Fludarabine, Cytarabine, and Granulocyte Colony-stimulating Factor Results in Improved Event-free Survival
Gautam Borthakur et al.
CANCER (2008)
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
Frederick R. Appelbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
R Cairoli et al.
BLOOD (2006)
Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type
WN Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
BF Goemans et al.
LEUKEMIA (2005)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
RA Larson et al.
LEUKEMIA (2002)
Share Paper
